














SAFETY AND EFFICACY OF DIODE 
LASER 
CYCLOPHOTOCOAGULATION IN 
THE TREATMENT OF GLAUCOMA 
AT GROOTE SCHUUR HOSPITAL 
Master of Medicine in Ophthalmology 
University of Cape Town 
 
MMED CANDIDATE 
Dr Ingrid Coetzee 
Student number - CTZING001 
Contact number - 083 725 9414 
Email address - ingridg@bgc.co.za 
 
SUPERVISOR 
Prof Nagib du Toit 
Contact number – (021) 404 3534 




















The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
 
1 | P a g e  
 





ACKNOWLEDGEMENTS AND CONTRTIBUTIONS……………………………....................5 
LIST OF TABLES………………………………………………………………………...........................6 
ABBREVIATIONS……………………………………………………………………………………………….8 
CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW……………………………........9 
 1.1: Introduction......................................................................................10 
 1.2: Literature search strategy.................................................................11 
 1.3: Literature review..............................................................................11 
REFERENCES…………………………………………………………………………………………………..16 
CHAPTER 2: PUBLICATION-READY MANUSCRIPT…………………………………...........18 
REFERENCES…………………………………………………………………………………………………..29 
APPENDICES…………………………………………………………………………………………………..31 
A: Data collection form............................................................................32 
B: Departmental Research Committee approval letter...........................33 
C: Human Research Ethics Committee approval letter............................34 
D: South African Ophthalmology Journal guidelines...............................35 
2 | P a g e
DECLARATION 
I, Ingrid Daniela Coetzee, hereby declare that the work on which this dissertation/thesis is based is 
my original work (except where acknowledgements indicate otherwise) and that neither the whole 
work nor any part of it has been, is being, or is to be submitted for another degree in this or any 
other university. 
I empower the university to reproduce for the purpose of research either the whole or any portion 
of the contents in any manner whatsoever. 
Signature: Date:  3/07/2018 





The primary objective of the study is to determine the efficacy of diode laser cyclophotocoagulation 
in terms of the amount of intraocular pressure (IOP) drop achieved in glaucoma patients at Groote 
Schuur Hospital. The secondary objective is to determine the safety of the procedure by analysing 
the complications that arose as a result of the cyclodiode treatment. 
 
Methods 
A retrospective file review was conducted on the diode laser cyclophotocoagulation (cyclodiode) 
procedures done at Groote Schuur Hospital Eye Clinic over a one year from 1 January 2014 to 31 
December 2014.  All the patients who received cyclodiode therapy at Groote Schuur Eye Clinic 
during this time period were included. There were no exclusion criteria. Data was collected on age, 
gender, laterality of procedure, pre-procedure visual acuity (VA), pre-procedure IOP, post-procedure 
VA at 3, 6 and 12 months, post-procedure IOP at 3, 6 and 12 months, medication pre- and post-
procedure, type of glaucoma, prior glaucoma surgery, total number of laser spots applied, average 
laser power used (mW), number of laser sessions received and complications of the procedure 
documented at 3 months post procedure. Data analysis was performed using Microsoft Excel 2016.  
 
Results 
There were 64 eyes treated over the 12-month period. Neovascular glaucoma was the most 
common glaucoma (44%). There was a significant difference between the pre- and the post-
treatment IOP at each of three (p<0.00001), six (p=0.00026), and 12 months (p=0.0012) (paired 
samples t-test) with a mean IOP drop of 10mmHg. There was no significant difference between the 
visual acuity before and after treatment at three months (p=0.13) (paired samples t-test). 
There was a significant difference between the visual acuity before and after treatment at six 
months (p=0.0078) and at 12 months (p=0.0083) (paired samples t-test). Before treatment, 98% 
of patients were receiving anti-glaucoma medical treatment and at three months after treatment, 
the number of eyes on medical treatment had decreased to 90% of the patients. This decrease was 
not significant (p=0.06) (chi-squared test). The mean number of three anti-glaucoma medications 
being used remained unchanged but the number of patients receiving oral anti-glaucoma treatment 
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Transscleral cyclodiode is a safe procedure with a mean IOP decrease exceeding 10mmHg. Although 
this may not be enough to allow the cessation of all anti-glaucoma medication, it is often enough to 
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Table one: Types of glaucoma  
Type of glaucoma  
 
Number (%) 
Neovascular glaucoma  28 (44%) 
 
Primary open angle glaucoma 18 (28%) 
 
Secondary open angle glaucoma  14 (22%) 
 
Primary closed angle glaucoma  2 (3%) 
 
Secondary closed angle glaucoma other than 
neovascular glaucoma   
1 (1.5%) 
 
Congenital glaucoma  1 (1.6%) 
 
 
Table two: Mean IOPs before and after treatment   
 
 
Mean IOP (mmHg) 
Pre-treatment (64 eyes) 36 (SD +/- 14.6)    
 
After 3 months (52 eyes) 21 (SD +/- 15.7)    
 
After six months (36 eyes) 23 (SD +/- 13.2)    
 
After 12 months (33 eyes) 22 (SD +/- 12.7)    
 
 
Table three: Mean LogMAR visual acuity before and after treatment  
 Mean LogMAR visual acuity (+/- SD) 
 
Pre-treatment (64 eyes) 2.2 (SD +/- 1.1)    
 
After 3 months (53 eyes) 2.1 (SD +/- 1.0)    
 
After 6 months (42 eyes) 2.2 (SD +/- 1.0)    
 
After 12 months (37 eyes) 
 
2.0 (SD +/- 1.1)    
 
 
Table four: Complications after treatment  








Loss of vision more than one line   
 
12 (23%) 
Intraocular inflammation  
 
4 (8%)  
Hypotony (IOP <5mmHg) 
 
2 (4%) 
Hyphaema  3 (6%) 
 
IOP spike 1 (2%) 
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Glaucoma is a common ocular condition in which the intraocular pressure (IOP) within the eye is too 
high causing eventual damage to the optic nerve. As such the main aim of treatment is to lower the 
intraocular pressure in order to limit or prevent irreversible damage to the optic nerve.  
 
The first-line treatment of glaucoma is medical therapy in the form of intraocular pressure lowering 
eye drops and/or systemic medications. Failing this the next option would be various surgical 
procedures, some more invasive than others.  
 
Diode laser cyclophotocoagulation is a non-invasive procedure that destroys the part of the eye 
responsible for producing and secreting the water inside the eye called aqueous humour and 
thereby reducing intraocular pressure. It is a procedure which has been available for many years and 
has been proven to be safe and effective in lowering the intraocular pressure. 
 
Groote Schuur Hospital eye clinic currently uses diode laser cyclophotocoagulation for a certain 
group of patients with glaucoma not responding to other treatment modalities, patients with 
previous failed glaucoma surgery and those presenting with painful, blind eyes. It has however been 
noted that diode laser cyclophotocoagulation is being used more and more as a primary modality to 
lower intraocular pressure either as definitive treatment or as a temporizing measure prior to safely 
performing glaucoma surgery. In our setting with poor patient follow-up, relatively limited resources 
and often reluctance to accept surgical treatment options, this may become a valuable option in the 
future. 
 
Since there is currently no universal treatment protocol for diode laser cyclophotocoagulation, it is 
necessary to evaluate the efficacy of the diode laser cyclophotocoagulation protocol used at Groote 
Schuur Hospital at present in terms of the amount of intraocular pressure drop and compare this to 
the known success rates noted in previous studies. Evaluation of the safety of the procedure done at 
Groote Schuur Hospital by looking at the complications experienced will also allow a comprehensive 
assessment of our current protocol. If diode laser cyclophotocoagulation at Groote Schuur Hospital 
is shown to be a safe and effective procedure, management protocols could be adjusted accordingly 
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to provide a more comprehensive and accommodating service to the glaucoma patients presenting 
to our facility. 
 
1.2 Literature search strategy 
The PubMed Health database was used to perform a search of the relevant literature in peer 
reviewed journals. The search was conducted using the following keywords: cyclophotocoagulation, 
cyclodiode, glaucoma + treatment, diode laser cyclophotocoagulation 
 
1.3 Literature review  
 
1.3.1 Introduction 
Glaucoma is a characteristic optic neuropathy diagnosed by identifying specific structural changes 
and functional loss1 and is the leading cause of irreversible blindness worldwide. 2  In 2010 it was 
estimated that 60.5 million people worldwide were affected by primary open-angle glaucoma 
(POAG) and primary angle-closure glaucoma (PACG).3 The World Health Organisation’s most recent 
estimation is that 4.5 million people worldwide are blind from glaucoma, accounting for 
approximately twelve percent of global blindness.1 When looking at the prevalence of blindness in 
Africa specifically, the literature from Lewallen et al suggested that in 2001 Africa had a blindness 
prevalence rate of approximately one percent.4 A more recent review by Naidoo et al found this 
prevalence rate to be slightly higher in 2010 with a rate of 1.3% reported. 5 The top 3 causes of 
blindness identified in this region of the world are cataract, glaucoma and trachoma4, with glaucoma 
being reported as the leading cause of global irreversible bindness.2, 3 This emphasises the 
magnitude of glaucoma as a clinical entity worldwide and in Africa and highlights the importance of 
adequate prevention and treatment of this disease. 
 
1.3.2 Glaucoma treatment 
There is very little known at this stage about primary prevention of glaucoma, however there are 
many options available when treating glaucoma with the aim of halting the disease process and 
preventing irreversible visual field loss and blindness.1 Medical therapy remains first-line treatment 
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followed by the various invasive and non-invasive surgical options available. One of the non-invasive 
surgical options for treating glaucoma is diode laser cyclophotocoagulation. 
 
1.3.3 Diode laser cyclophotocoagulation 
Diode laser cyclophotocoagulation (cyclodiode) is a cyclodestructive procedure that lowers 
intraocular pressure by destroying part of the ciliary body in the eye responsible for aqueous 
secretion and thereby reducing aqueous production.6 Ciliary body ablation or cyclodestruction as a 
glaucoma treatment modality has been used for many decades and has been described as a 
treatment option since the 1930s. 7  The past nine decades have seen advances in various 
cyclodestructive techniques with the aim of focusing the necessary energy at the correct tissues with 
as minimal collateral damage as possible. 7 This in turn decreases the likelihood of complications and 
increases the efficacy of the procedure with postoperative outcomes closer to the other available 
invasive and non-invasive glaucoma treatment modalities. 7   
 
The original cyclodestructive techniques involved cyclodiathermy and cryotherapy.8 Various studies 
done in the 1940s and 1950s showed poor outcomes using cyclodiathermy in terms of safety as well 
as suboptimal clinical response.7 Cryotherapy was then tried as a cyclodestructive technique by 
Bietti in 1950 and was found to be more effective and less destructive than cyclodiathermy but still 
with many associated complications.7  Laser photocoagulation of the ciliary body or 
cyclophotocoagulation is a newer method now used for ciliary body ablation. Initially this was done  
using xenon arc photocoagulation in 19617, followed in the 1970s by ruby laser which was 
subsequently surpassed a year later by 1064-nm neodymium/YAG laser.7, 9-11 Diode laser was 
introduced in 1984, with good results shown a few years later in the 1990s. 7 The latest method 
involves using an 810-nm semiconductor diode laser.9, 11 Diode laser cyclophotocoagulation is the 
ideal method at present due to the selective absorption of the 810-nm wavelength by the uveal 
melanin as well as deeper ciliary body ablation and lower complication rates.9, 11-14 When comparing 
the three main types of lasers used for cyclodestruction, diode laser seems to be preferred due to its 
cost, efficiency and easy portability.7 
 
Diode laser cyclophotocoagulation can be delivered through various ways in order to achieve the 
desired effect of lowering intraocular pressure. Transscleral semiconductor diode laser or cyclodiode 
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involves the use of light energy emitted from a semiconductor solid state diode laser system to 
ablate the ciliary body.7 This light energy emitted is near the infrared spectrum at 810nm which is 
strongly absorbed specifically by melanin containing structures, such as the pigmented ciliary body 
epithelium.7 It is delivered using a continuous delivery of diode laser to destroy the ciliary body and 
thereby reduce aqueous production and, in turn, intraocular pressure.2, 7 The intraocular pressure 
lowering effect of transscleral cyclodiode has been shown to be closely correlated with the number 
of laser spots applied; this at the expense of potentially increasing complications based on the fact 
that an increased number of laser spots results in an increased amount of laser power used in the 
eye with a possible increase in complications. 2 Collateral damage to the surrounding structures 
within the eye is thought to be the possible reason for the severity of these complications.2 
 
A more recently developed technique of micropulse transscleral cyclophotocoagulation is showing 
promise and offers a variation to the well-known technique of traditional transscleral cyclodiode 
laser.2, 7, 15 With this technique short (microsecond), multiple repetitive bursts of laser energy are 
delivered to the tissue being targeted during the “on-cycle”.2, 7, 15 These bursts of energy build up to 
a photocoagulative state in the melanin containing tissues such as the pigmented epithelium of the 
ciliary body, whilst the non-pigmented tissues never attain this coagulative state due to their lower 
absorption rate of the energy.2, 7 The “on-cycles” are followed by “off-cycles” during which time the 
surrounding tissues have time to cool and remain below the coagulative threshold, which in turn is 
believed to prevent collateral damage to the surrounding tissues with the hope of further decreasing 
associated complications.2, 7, 15 
 
Another technique of diode delivery is endoscopic cyclophotocoagulation where the ciliary 
processes are ablated using continuous-wave 810nm diode laser and direct endoscopic visualisation 
of the ciliary processes.7 Since this process involves either a limbal incision or pars plana approach, it 
is often done as a combined procedure in patients requiring anterior or posterior segment surgery 
for other related or unrelated reasons.7 
 
Looking specifically at the method of diode delivery used at Groote Schuur Hospital eye clinic at 
present, transscleral cyclodiode laser is performed using a G-probe with a fibreoptic pit which emits 
the necessary diode laser energy.7, 9 The G-probe is positioned at the limbus and designed in such a 
way that when positioned correctly the fibreoptic pit is in the correct position to direct the laser 
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energy onto the ciliary processes and ablate them.7 The usual technique used with this method is 
“pop titrated” laser delivery where the laser energy applied is titrated up or down depending on 
whether or not a “pop” is heard. The “pop” sound heard represents micro-explosions of the ciliary 
process after adequate energy has been applied and absorbed by the tissue.7, 16 The other available 
method is using fixed energy laser delivery where the energy is fixed at 2000mW (72J).16 
 
1.3.4 Success and efficacy of diode laser cyclophotocoagulation 
There is no universal definition of success, which makes a comparison of success rates from different 
studies problematic. A literature search and review conducted by the American Academy of 
Ophthalmology was published in 2001 and included literature from the years 1968 to 2000. This 
review noted that the success rate of achieving an IOP below 22mmHg after diode laser 
cyclophotocoagulation in adults ranged between 70% and 81%.13 A review of more recent articles 
between the years of 2008 to 2017 showed a success rate of achieving an IOP below 22mmHg of 
between 61% and 87%.11, 12, 17-20  There is a more recent study by Bendel et al that suggests that 
higher success rates of above 88% with less postoperative complications may be achieved by 
performing transscleral cyclodiode laser in an operating theatre.21 This is believed to be due to 
better monitored anaesthesia resulting in improved patient tolerability and thus more accurate laser 
burn applications.21 There are recent studies that have reported on the safety and efficacy of 
micropulse cyclodiode laser compared to the traditional continuous wave transscleral diode laser, 
and although few in number, they have shown micropulse to be as safe and effective as the 
traditional cyclodiode delivery method.2 
 
1.3.5 Indications for diode laser cyclophotocoagulation 
Transscleral cyclophotocoagulation has typically been reserved for eyes with refractory glaucoma 
and potentially poor visual prognosis.7  It has however been noted that diode laser 
cyclophotocoagulation is being used more and more frequently as a primary or secondary surgical 
procedure on eyes with various types of glaucoma to lower IOP either as definitive treatment or as 
temporizing measure prior to safely performing glaucoma surgery.11, 22, 23 Promising results have also 
been shown on eyes with good presenting vision and good expected visual potential. 24, 25  
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The current indications for the use of diode laser cyclophotocoagulation at Groote Schuur Hospital 
eye clinic are patients with refractory glaucoma, failed glaucoma surgery cases, and those presenting 
with painful, blind eyes. The follow-up and care of a patient who has undergone penetrating 
glaucoma surgery is extremely intensive and often involves further multiple interventions to ensure 
bleb functioning and success of the procedure.  In our setting with poor patient follow-up and 
compliance, as well as relatively limited resources, expanding the indications for diode laser 
cyclophotocoagulation and including it as a primary or secondary treatment modality or even as a 
treatment option on eyes with good presenting vision may become an option in the future for the 
management of our glaucoma patients. 
 
1.3.6 Complications of diode laser cyclophotocoagulation 
Some of the main known complications of all cyclodestructive procedures include hypotony, 
suprachoroidal haemorrhage, prolonged ocular inflammation, postoperative pain, visual loss, 
phthisis bulbi and retinal detachment. These have however been shown to be a less frequent 
occurrence when specifically using diode laser cyclophotocoagulation as opposed to the other 
cyclodestructive modalities.6, 9, 13, 26 Complications specific to diode laser cyclophotocoagulation are 
potential conjunctival surface burns as well as the increased perilimbal pigmentation associated with 
this.13  
 
1.3.7 Rationale for research 
Since there is currently no internationally accepted definitive treatment protocol for diode laser 
cyclophotocoagulation9, 16, our primary aim is to evaluate the efficacy of the diode laser 
cyclophotocoagulation protocol currently used at Groote Schuur Hospital in terms of the amount of 
IOP drop with each treatment session and compare this to known success rates as discussed above. 
Evaluation of the safety of the procedure done at Groote Schuur Hospital by looking at the 
complications experienced will be our secondary aim and will allow a comprehensive assessment of 
our current protocol. If diode laser cyclophotocoagulation at Groote Schuur Hospital is shown to be 
a safe and effective procedure, management protocols would be adjusted accordingly to provide a 
more comprehensive and accommodating service to the glaucoma patients presenting to our 
facility. 
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INTRODUCTION 
Glaucoma is a characteristic optic neuropathy diagnosed by identifying specific structural changes 
and functional loss1 and is the leading cause of irreversible blindness worldwide. 2  In 2010 it was 
estimated that 60.5 million people worldwide were affected by primary open-angle glaucoma 
(POAG) and primary angle-closure glaucoma (PACG).3 The World Health Organisation’s most recent 
estimation is that 4.5 million people worldwide are blind from glaucoma, accounting for 
approximately twelve percent of global blindness.1 When looking at the prevalence of blindness in 
Africa specifically, the literature from Lewallen et al suggested that in 2001 Africa had a blindness 
prevalence rate of approximately one percent.4 A more recent review by Naidoo et al found this 
prevalence rate to be slightly higher in 2010 with a rate of 1.3% reported. 5 The top 3 causes of 
blindness identified in this region of the world are cataract, glaucoma and trachoma4, with glaucoma 
being reported as the leading cause of global irreversible bindness.2, 3 This emphasises the 
magnitude of glaucoma as a clinical entity worldwide and in Africa and highlights the importance of 
adequate prevention and treatment of this disease. 
 
There is very little known at this stage about primary prevention of glaucoma, however there are 
many options available when treating glaucoma with the aim of halting the disease process and 
preventing irreversible visual field loss and blindness.1 Medical therapy remains first-line treatment 
followed by the various invasive and non-invasive surgical options available. One of the non-invasive 
surgical options for treating glaucoma is diode laser cyclophotocoagulation or cyclodiode. 
 
Transscleral cyclophotocoagulation has typically been reserved for eyes with refractory glaucoma 
and potentially poor visual prognosis.6  It has however been noted that diode laser 
cyclophotocoagulation is being used more and more frequently as a primary or secondary surgical 
procedure on eyes with various types of glaucoma to lower IOP either as definitive treatment or as 
temporizing measure prior to safely performing glaucoma surgery.7-9 Promising results have also 
been shown on eyes with good presenting vision and good expected visual potential. 10, 11  
 
The current indications for use of diode laser cyclophotocoagulation at Groote Schuur Hospital eye 
clinic are patients with refractory glaucoma, failed glaucoma surgery cases, and those presenting 
with painful, blind eyes. The follow-up and care of a patient who has undergone penetrating 
glaucoma surgery is extremely intensive and often involves further multiple interventions to ensure 
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bleb functioning and success of the procedure.  In our setting with poor patient follow-up and 
compliance, a reluctance to fully accept invasive surgical options, as well as relatively limited 
resources, expanding the indications for diode laser cyclophotocoagulation and including it as a 
primary or secondary treatment modality or even as a treatment option on eyes with good 
presenting vision may become an option in the future for the management of our glaucoma 
patients. 
 
Since there is currently no definitive treatment protocol for diode laser cyclophotocoagulation 
worlwide12, 13, our primary aim is to evaluate the efficacy of the diode laser cyclophotocoagulation 




A retrospective file review of the diode laser cyclophotocoagulation procedures done at Groote 
Schuur Eye Clinic from 1 January 2014 to 31 December 2014 was conducted and quantitative data 
was collected. This was conducted after obtaining ethical approval from the University of Cape 
Town’s Faculty of Health Sciences Human Research Ethics Committee. The inclusion criteria included 
all patients over the age of 13 years old who received diode laser cyclophotocoagulation therapy at 
Groote Schuur Hospital Eye Clinic over this 12-month period. Data including gender, age, pre- and 
post-procedure visual acuity at three, six and 12 months, pre- and post-procedure intraocular 
pressure at three, six and 12 months, type of glaucoma, prior glaucoma surgery, number of laser 
spots applied, total laser power used, number of cyclodiode sessions given and complications 
experienced at three months post-procedure was collected. The data was entered into an excel 
spreadsheet and analysed using the excel 2016 data analysis software. The paired samples t-test and 
chi-squared test were used to test significance of associations. 
 
RESULTS 
There were 64 eyes treated over the 12-month period in 2014. 
Thirty-three (52%) were male and 31 (48%) were female. 
The age range of the patients was 15 to 90 years, with a mean age of 61 years (SD +/- 14.3 years). 
Table one shows the types of glaucoma in the treated eyes. 
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Table one: Types of glaucoma  
Type of glaucoma  
 
Number (%) 
Neovascular glaucoma  28 (43.8%) 
 
Primary open angle glaucoma 18 (28.1%) 
 
Secondary open angle glaucoma  14 (21.9%) 
 
Primary closed angle glaucoma  2 (3.1%) 
 
Secondary closed angle glaucoma other than 
neovascular glaucoma   
1 (1.6%) 
 
Congenital glaucoma  1 (1.6%) 
 
 
Thirty-seven eyes (58%) did not undergo previous surgery and 27 eyes (42%) did undergo previous 
surgery. 
Forty-eight eyes (76%) had one laser treatment session, 13 eyes (21%) had two laser treatment 
sessions, and two eyes (3%) had three laser treatment sessions. The mean number of laser spots 
applied at each session was 17, and the mean laser power setting used was 1953mW. 
With loss to follow-up, 52 patients were reviewed after three months, 36 after six months, and 33 
after 12 months. 
Table two shows the mean pre-treatment IOP and the mean post treatment IOP after three, six, and 
12 months. 
 
Table two: Mean IOPs before and after treatment   
 
 
Mean IOP (mmHg) 
Pre-treatment (64 eyes) 36 (SD +/- 14.6)    
 
After 3 months (52 eyes) 21 (SD +/- 15.7)    
 
After six months (36 eyes) 23 (SD +/- 13.2)    
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There was a significant difference between the pre-treatment IOP and the post-treatment IOP at 
each of three months (p<0.00001), six months (p=0.00026), and 12 months (p=0.0012) (paired 
samples t-test) with a mean IOP drop in excess of 10mmHg. Success in our study is defined as IOP 
post-treatment of less than 22mmHg. This is based on the definition of success in most of the studies 
included in our literature review. At 3 months post procedure, 71% of eyes had an IOP of less than 
22mmHg. 
Before treatment, 62 of 63 eyes (98%) were receiving anti-glaucoma medical treatment. No data was 
available for one patient. At three months after treatment, the number of eyes on medical 
treatment had decreased to 47 of 52 eyes (90%), and this decrease was not significant (p=0.06) (chi-
squared test). The mean number of three anti-glaucoma medications being used remained 
unchanged. Patients receiving oral anti-glaucoma treatment decreased from 58.7% to 36.5% post-
procedure. 
For analysis, the Snellen visual acuities were converted to LogMAR visual acuities.14 
Table three shows the mean pre-treatment visual acuities and the mean post-treatment visual 
acuities after three months, six months, and 12 months. 
 
Table three: Mean LogMAR visual acuity before and after treatment  
 Mean LogMAR visual acuity (+/- SD) 
 
Pre-treatment (64 eyes) 2.2 (SD +/- 1.1)    
 
After 3 months (53 eyes) 2.1 (SD +/- 1.0)    
 
After 6 months (42 eyes) 2.2 (SD +/- 1.0)    
 
After 12 months (37 eyes) 
 
2.0 (SD +/- 1.1)    
 
 
There was no significant difference between the visual acuity before and after treatment at three 
months (p=0.13) (paired samples t-test). There was a significant difference between the 
visual acuity before and after treatment at six months (p=0.0078) and at 12 months (p=0.0083) 
(paired samples t-test).  
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Visual acuity decreased in 15.4%, 25% and 30% of patients at three, six and 12 months 
post-treatment respectively. Visual acuity improved in 7.7%, 5.6% and 3% of patients 
at three, six and 12 months post-treatment respectively. The visual acuity decreased to 
no light perception in 4 (8%) patients at three, six and 12 months post-treatment. 
 
Table four shows the complications documented after treatment. 
 







Loss of vision more than one line   
 
12 (23%) 
Intraocular inflammation  
 
4 (8%)  
Hypotony (IOP <5mmHg) 
 
2 (4%) 
Hyphaema  3 (6%) 
 
IOP spike 1 (2%) 
 
 
There were 60% of patients who experienced no complications. Of the 40% who experienced 
complications, 23% involved loss of vision or more than one Snellen line. The remaining 17% had 
milder complications which resolved with the appropriate treatment. 
 
DISCUSSION 
Transscleral cyclodiode treatment was effective in reducing the intraocular pressure, with a drop in 
the mean IOP from 36mmHg before treatment to 21mmHg after three months. This drop in IOP was 
sustained in the patient group followed up over the following nine months. It should however be 
noted that there was a loss of data due to loss of follow-up or incomplete case notes in 19 patients 
(29%). It was safe to use, with 60% of patients experiencing no complications and 17% experiencing 
mild complications which were not sight-threatening. 
 
Evaluating the success and efficacy of diode laser cyclophotocoagulation when looking at previous 
studies on this subject is problematic. There is no universal definition of success which makes the 
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comparison of success rates difficult. However, the majority of the literature reviewed base their 
success rate on achieving an IOP of below 22mmHg after the procedure. This was thus the success 
rate we used in our study. A literature search and review conducted by the American Academy of 
Ophthalmology which was published in 2001 noted that the success rate of achieving an IOP below 
22mmHg after diode laser cyclophotocoagulation in adults ranged between 70% and 81%.15 A review 
of more recent articles between the years of 2008 to 2018 also showed a success rate of achieving 
an IOP below 22mmHg of between 61% and 87%.6, 7, 16-20 In our case series, 71% of eyes had an IOP 
below 22mmHg at three months which was sustained over the following nine months. This success 
rate is notably comparable to those found in our literature review.  
 
Whilst it would be most desirable for patients not to need anti-glaucoma medication after 
treatment, disappointingly 90% of eyes remained on adjuvant medical treatment after cyclodiode. 
Similar to the results reported in a study by Bloom et al, the percentage of patients not requiring 
anti-glaucoma medication increased from 1.6% pre-treatment to be 9.6% post-treatment.21 
Reducing and, if possible, stopping anti-glaucoma medications is desirable in all patients in order to 
increase compliance and limit potential side effects of the treatment. The oral anti-glaucoma 
medications in particular have the most unwanted side effects when compared to topical meds and 
thus decreasing the need for their long-term use is attractive to both the ophthalmologist and 
patient. Previous studies have shown variable results in terms of the decrease in percentage of 
patients requiring oral anti-glaucoma medications pre- and post-treatment. The figures from our 
literature review range from 45% to 10% decrease in number of patients on oral medication.20, 22, 23 
We found similar results in our study with 59% of patients requiring the use of oral anti-glaucoma 
medication prior to treatment with cyclodiode, and only 37% remaining on oral medication after 
treatment. 
 
The main potential complications of all cyclodestructive procedures include hypotony, 
suprachoroidal haemorrhage, prolonged ocular inflammation, postoperative pain, visual loss, 
phthisis bulbi and retinal detachment.12, 15, 24, 25 In this study, most eyes (60%) had no complications 
from the cyclodiode at 3 months post-procedure. Only four eyes (8%) had documented intraocular 
inflammation which was successfully treated with topical medication, and 12 (23%) patients 
experienced loss of vision of more than one Snellen line. This leaves 77% of patients having either no 
change in visual acuity or an improvement in vision at 3 months post-procedure. All of these figures 
are comparable to the international literature included in our review.8, 11, 21 Of the 12 patients with 
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loss of visual acuity, nine patients experienced the loss of vision only with no other documented 
complication related to the procedure that could explain the visual loss. The three remaining 
patients experienced loss of vision plus either intraocular inflammation or hyphaema which could 
account for this. Of the nine patients with documented loss of vision of more than one Snellen line, 
five patients had a poor prognosis pre-procedure Snellen visual acuity of count fingers or worse. The 
remaining four patients had Snellen visual acuities of better than 6/24 with known uveitis, 
pseudoexfoliation or primary angle-closure glaucoma. It would have been helpful to quantitatively 
document, through visual field or optic nerve head OCT tests as well as a full clinical examination, if 
the visual loss in these patients was part of the natural progression of the glaucoma or due to 
another identifiable cause. There were four patients (8%) whose visual acuity decreased at 3 months 
post procedure to no light perception. All of these patients had neovascular glaucoma with poor 
presenting visual acuities. One had a presenting VA of hand movements and the remaining three 
had initial VA of light perception. 
 
The main weaknesses with our study are its retrospective nature, with all the problems and 
limitations implicit in that, and lack of information recorded to try explain the reasons for visual loss 
post-procedure. Another limitation was unfortunately that 14 patients (22%) were lost to follow-up 
in the 12-month period after the procedure and 17 patients (27%) had case notes that were either 
incomplete or missing. 
 
There are a number of considerations in planning appropriate strategies for glaucoma management 
in middle income and low income African countries. Patients with cataracts (often termed “white 
blindness” because of the white pupil present), which is, happily, the commonest cause of blindness 
in Africa, may be effectively treated and cured of their blindness with cataract surgery.  Patients with 
chronic glaucoma (often termed “black blindness” because of the black pupil present), which is the 
second leading cause of blindness in Africa, present more of a challenge. The reason for this is 
multifaceted and complex. Glaucoma in Africans often has an earlier onset plus a more aggressive 
course requiring close lifelong follow-up, regular visits and strict IOP control.4, 11 Medical treatment is 
a problem. The lack of availability of medication plus the cost of medication, as well as poor patient 
understanding are likely to result in poor compliance with inadequate intraocular pressure control 
and subsequent progression of disease.11, 26 Surgical treatment also poses a problem. Patients often 
have low acceptance of glaucoma surgery and may have difficulty understanding and accepting the 
differences between their glaucoma causing “black blindness” and their neighbour’s cataract or 
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“white blindness”. This in turn leads to them not understanding fully why the surgery they 
underwent for their glaucoma did not “cure them” of their blindness and improve their visual 
functioning when compared to the cataract surgery which restored vision to their neighbour.11, 26  
This could not only result in a negative marketing impact on cataract surgery, but also on the 
willingness of patients to undergo often very necessary glaucoma surgery in order to preserve their 
remaining visual function.  Many African eye surgeons are also often reluctant to offer patients the 
necessary glaucoma surgery for fear of the possibility of encountering the known complications that 
can occur with these surgeries and for fear of being seen to worsen the patient’s visual functioning.11 
The well documented propensity of black African eyes to fibrosis and failure of the drainage bleb 
after conventional drainage surgery, especially if antimetabolites are not used as an adjunct, 
supports this fear. 11, 27, 28 
 
The ideal “silver bullet” for the management of glaucoma would be a safe, inexpensive, technically 
simple “once off” intervention that adequately permanently lowers the intraocular pressure, and 
that can be done as an outpatient procedure as soon as the diagnosis is made, obviating the need 
for life long medical treatment, obviating any risk of confusion with cataract surgery, and obviating 
the risk of failure or other complications after conventional drainage surgery and eliminating patient 
fears of surgical intervention. Some form of laser treatment might most closely approximate this 
ideal.  
 
Transscleral cyclodiode laser treatment therefore could have a potential role as first line treatment 
for chronic glaucoma in middle-income and low-income countries such as those found in Africa. The 
specific advantages being its small size, portability, low cost to run and ease of use, together with 
the convenience of less post-procedural complications and a less intensive follow-up schedule 
required when compared to conventional incisional glaucoma surgery.9 Notwithstanding the fact 
that it is generally reserved for the treatment of eyes with end stage disease in which more 
conventional medical treatment or surgery is ineffective in controlling the intraocular pressure 6, 
there are some proponents for its use as a first line treatment. 6, 8, 9 This is particularly true for 
patients with primary open angle glaucoma in which the highest success rates have been found by 
numerous authors when using transscleral cyclodiode as a primary treatment modality.9 This finding 
is of great significance for African countries where the highest prevalence of POAG exists11 and 
where a procedure such as transscleral cyclodiode may be more widely accepted than invasive 
surgery. A recent study by Abdull et al11 conducted in Nigeria echoed these promising findings and 
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confirmed that transscleral cyclodiode was safe and effective, as well as better accepted by patients 
as the primary treatment in seeing eyes with POAG in their setting. This finding could have positive 
implications in South Africa, where the ethnicity, cultural beliefs of a great proportion of the 
population and resource scarcity closely match those of the Nigerian population. 
  
CONCLUSION 
In our case series, we have found transscleral cyclodiode laser treatment to be a safe procedure in 
lowering the intraocular pressure with a comparable success rate to previous authors of 71%. The 
mean IOP decrease seen in our patients exceeded 10mmHg and although this may not be enough to 
obviate the need for anti-glaucoma medication, it is often enough to allow the cessation of oral anti-
glaucoma medication with its undesirable systemic side-effects. Our case series shows that the 
transscleral cyclodiode protocol currently used at Groote Schuur Hospital is effective and safe. With 
this knowledge it will be possible to further look into expanding our indications for cyclodiode 
procedures and possibly start using the procedure more frequently as a primary treatment modality.  
Further research looking into the long-term complications and elaborating on the causes of visual 
loss in these patients is warranted. A prospective study to assess the use of cyclodiode as a primary 
treatment modality at Groote Schuur Hospital would also be of great use in this setting where poor 
follow-up and compliance, as well as a lack of understanding into the disease process necessitates a 
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CASE NUMBER  CODING 
FILE NUMBER   
GENDER   
AGE   
SIDE   
PRE-OP VA   
PRE-OP IOP   
POST-OP VA 3/12   
POST-OP VA 6/12   
POST-OP VA 12/12   
POST-OP IOP 3/12   
POST-OP IOP 6/12   
POST-OP IOP 12/12   


















TYPE OF GLAUCOMA   
PRIOR GLAUCOMA SURGERY   
TOTAL SPOTS APPLIED   
TOTAL LASER POWER (mW)   
NUMBER OF SESSIONS   
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APPENDIX D: South African Ophthalmology Journal guidelines 
 
